Search company, investor...
RetroScreen Virology company logo

RetroScreen Virology

Founded Year



Grant | Alive

Total Raised


Last Raised

$280K | 9 yrs ago

About RetroScreen Virology

Retroscreen Virology has developed a business system with two principal units. The first is a Clinical Services business built around Human Viral Challenge Model and the second is a Translational Research (Pre-Clinical) business, built around in-house expertise on testing antivirals and virucidals in-vitro.

Headquarters Location

42 New Road

London, England, E1 2AX,

United Kingdom

+44 (0) 20 7756 1300

Missing: RetroScreen Virology's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: RetroScreen Virology's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

RetroScreen Virology Patents

RetroScreen Virology has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Vaccines, Immunology, Immune system, Influenza, Clusters of differentiation


Application Date


Grant Date



Related Topics

Vaccines, Immunology, Immune system, Influenza, Clusters of differentiation



Latest RetroScreen Virology News

Retroscreen Virology Group PLC Stock Rating Lowered by Numis Securities Ltd (HVO)

Sep 24, 2015

Tweet Retroscreen Virology Group PLC (LON:HVO) was downgraded by research analysts at Numis Securities Ltd to an “add” rating in a research report issued on Thursday, Analyst Ratings Net reports. They currently have a GBX 340 ($5.28) target price on the stock. Numis Securities Ltd’s price objective would indicate a potential upside of 10.93% from the stock’s current price. The stock’s 50 day moving average is GBX 302.63 and its 200 day moving average is GBX 292.53. Retroscreen Virology Group PLC has a 12-month low of GBX 225.25 and a 12-month high of GBX 345.00. Retroscreen Virology Group PLC ( LON:HVO ) is the United Kingdom-based holding company. Retroscreen is a virology healthcare business that provides clinical services, focused on the Human Challenge Model (HCM) primarily to pharmaceutical companies and biotechnology organizations. The Company has grown and developed the HCM for evidencing the efficiency of antiviral and viral therapeutics in RSV, flu and cold. The Company has only one reportable segment, which is medical and scientific research services. Retroscreen has its own technology platform called hVIVO for the research and development of new therapies. It carries out all its activities from the United Kingdom. The subsidiaries of the company are Retroscreen Virology Limited and Retroscreen Virology Services Limited. Receive News & Ratings for Retroscreen Virology Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retroscreen Virology Group PLC and related companies with's FREE daily email newsletter . Leave a Reply

RetroScreen Virology Frequently Asked Questions (FAQ)

  • When was RetroScreen Virology founded?

    RetroScreen Virology was founded in 1989.

  • Where is RetroScreen Virology's headquarters?

    RetroScreen Virology's headquarters is located at 42 New Road, London.

  • What is RetroScreen Virology's latest funding round?

    RetroScreen Virology's latest funding round is Grant.

  • How much did RetroScreen Virology raise?

    RetroScreen Virology raised a total of $280K.

  • Who are the investors of RetroScreen Virology?

    Investors of RetroScreen Virology include Corridor Growth Fund and IP Group.

  • Who are RetroScreen Virology's competitors?

    Competitors of RetroScreen Virology include Esperance Pharmaceuticals, Immune Targeting Systems, SpiroGen, LigoCyte Pharmaceuticals, Quintessence Biosciences and 13 more.

Compare RetroScreen Virology to Competitors

Choice Research of Birmingham

Choice Research of Birmingham is a company that manages clinical development trials.


Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Anterion Therapeutics

Anterion Therapeutics inc is engaged in the research, development, preclincal and human clinical testing.

Oncology Research Therapeutics

Oncology Research Therapeutics, Inc. is dedicated to providing and discovering cancer diagnostics that improve the lives of patients suffering from a wide array of cancers. They also provide R&D services that improve drug development for the Biotech and Pharmaceutical industries.


Apath is a pharmaceutical discovery and development company with a focus on the hepatitis C virus ("HCV") and other human viral pathogens. Apath was founded by Charles M. Rice, Ph.D., currently Professor of Molecular Microbiology, Rockefeller University and formerly of the Washington University (St. Louis) School of Medicine. Apath is engaged in the commercial application of virology and viral genetics to discover and develop a broad range of diagnostic and therapeutic products for viral infections, and for applications using viruses as vectors. Apath's primary focus is on RNA viruses. RNA viruses account for the majority of viruses which are human pathogens. In addition to HCV, they include several medically important viruses such as influenza, respiratory syncytial virus ("RSV"), and hemorrhagic fever viruses (e.g., Ebola).

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.